Action Cabana Target Leading Se...

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

21,0027

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

21,0027

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Dr. Gerald Yakatan, Former President and CEO of Avanir Pharmaceuticals, Joins Cobalis Corp. Board of Directors

IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical development company...

Cobalis Corp. PreHistin(TM) Approval Process to Be Conducted by OTC Division of FDA

FDA's Office of Nonprescription Products Will Now Handle Marketing Approval Process for Anti-Allergy Drug PreHistin(TM) IRVINE, Calif., Jan. 19...

Cobalis Corp. Adds CFO to Management Team

Thomas Stankovich, Former Vice President and Chief Financial Officer of MP Biomedicals, Ribapharm and ICN / Valeant Pharmaceuticals Joins Cobalis...

Cobalis Corp. PreHistin(TM) to Be Granted European Union Patent

European Patent Office Allows New Patent for PreHistin(TM) -- 'Cyanocobalamin Treatment in Allergic Disease' IRVINE, Calif., Nov. 2...

Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial

Safe, Non-Drowsy PreHistin(TM) Achieves Clinical and Statistical Significance (p= 0.0028) Versus Placebo; Study Demonstrates Dramatic Reduction in...

Legal Opinion Reinforces Cobalis Patent

IRVINE, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical biotech company...

Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms i

Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms in Humans IRVINE...

Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange

Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange IRVINE, Calif., Oct...

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange IRVINE, Calif., Aug. 27...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cabana Target Leading Sector Conservative ETF (CLSC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

CLSC Dernières nouvelles

Dr. Gerald Yakatan, Former President and CEO of Avanir Pharmaceuticals, Joins Cobalis Corp. Board of Directors

Cobalis Corp. PreHistin(TM) Approval Process to Be Conducted by OTC Division of FDA

Cobalis Corp. Adds CFO to Management Team

Cobalis Corp. PreHistin(TM) to Be Granted European Union Patent

Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial

Legal Opinion Reinforces Cobalis Patent

Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms i

Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Cabana Target Leading Sector Conservative ETF (CLSC) Cours

Cabana Target Leading Sector Conservative ETF (CLSC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

CLSC Dernières nouvelles

Dr. Gerald Yakatan, Former President and CEO of Avanir Pharmaceuticals, Joins Cobalis Corp. Board of Directors

Cobalis Corp. PreHistin(TM) Approval Process to Be Conducted by OTC Division of FDA

Cobalis Corp. Adds CFO to Management Team

Cobalis Corp. PreHistin(TM) to Be Granted European Union Patent

Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial

Legal Opinion Reinforces Cobalis Patent

Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms i

Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange

Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP